Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

LNCAP in-vitro treatment with androgen receptor targeting drugs

ABSTRACT: LNCAP in-vitro treatment with androgen receptor targeting drugs

PROVIDER: PRJNA872110 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR21162416_1.fastq.gz	Fastqsanger.gz
	SRR21162416_2.fastq.gz	Fastqsanger.gz
	SRR21162417_1.fastq.gz	Fastqsanger.gz
	SRR21162417_2.fastq.gz	Fastqsanger.gz
	SRR21162418_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 32

Similar Datasets

LNCAP in-vitro treatment with androgen receptor targeting drugs

Project description:Gene expression in LNCaP cells after treatment with the androgen receptor targeting drugs bicalutamide (BIC), enzalutamide (ENZ) and apalutamide (ARN) in the presence or absence of dihydrotestosterone (DHT).

2022-09-07 | GSE211781 | GEO

Androgen receptor RIME using LNCaP cells

Project description:Rapid immunoprecipitation mass spectrometry of endogenous protein (RIME) was conducted to examine interactome of androgen receptor (AR) in LNCaP cells.

2021-09-10 | PXD024030 | JPOST Repository

Inhibition of nucleotide biosynthesis to enhance responses to drugs targeting androgen biosynthesis and the androgen receptor. [RNA-Seq]

Project description:RNA-Seq analysis of prostate cancer cells derived from xenografts treated daily with drugs targeting androgen biosynthesis and the androgen receptor.

2024-02-21 | GSE142195 | GEO

Inhibition of nucleotide biosynthesis to enhance responses to drugs targeting androgen biosynthesis and the androgen receptor. [miRNA-Seq]

Project description:RNA-Seq (miRNA) analysis of prostate cancer cells derived from xenografts treated daily with drugs targeting androgen biosynthesis and the androgen receptor.

2024-02-21 | GSE142193 | GEO

Inhibition of nucleotide biosynthesis to enhance responses to drugs targeting androgen biosynthesis and the androgen receptor

Project description:Inhibition of nucleotide biosynthesis to enhance responses to drugs targeting androgen biosynthesis and the androgen receptor

| PRJNA596174 | ENA

Effects of small molecules targeting the androgen receptor DNA-binding domain on prostate cancer cell transcriptome

Project description:Prostate cancer is a leading cause of cancer related death among men. Current Androgen Receptor (AR) antagonists often target the ligand binding domain (LBD). However, occurrence of resistance to drugs targeting the LBD is common due to emergence of mutations in the LBD or constitutively active variants that lack the LBD itself. Two novel small molecules, VPC-17005 and VPC-14449 targeting the DNA-binding domain have been developed and published previously. In this study, LNCaP cells were treated with one of these drugs or the well-established AR antagonist Enzalutamide, and the transcriptomic changes have been determined using RNA-seq analysis.

2019-07-20 | GSE127816 | GEO

Androgen receptor-coregulators hormone responsiveness LNCaP / GSF

Project description:The text description is: LNCaP are androgen receptor expressing prostate carcinoma cells. Genital skin fibroblasts also express the androgen receptor. Cells were either proliferating or they were G0-arrested. Treatment of cells was performed with either the androgen DHT (dihydrotestosterone), the androgen analogue R1881 (methyltrienolone), or the solvent ethanol. Some hybridizations were performed in the type 1 design. In these cases, the hormone treated sample was hybridized against the ethanol treated sample on the same microarray. Hormone mediated induction or repression of gene transcription can directly be deduced from R/G normalized ratios on arrays. For other experiments, the ethanol treated control and the hormone treated experiment were hybridized on separate microarrays against a common reference of RNA. This reference was composed out of common reference batch CRG (50%) and a fibroblast RNA (50%). This reference was called mixed reference. For all experiments, the same batch of mixed reference was used. A compound treatment design type is where the response to administration of a compound or chemical (including biological compounds such as hormones) is assayed. Compound Based Treatment: Ethanol, R1881 (methyltrienolone), or DHT (dihydrotestosterone) Cell Line: LNCaP (prostate cancer) or foreskin fibroblasts Culture Synchrony: proliferation / Go-arrest Computed

2010-07-01 | E-GEOD-4454 | biostudies-arrayexpress

Androgen receptor-coregulators hormone responsiveness LNCaP / GSF

2006-10-12 | GSE4454 | GEO

Inhibition of nucleotide biosynthesis to enhance responses to drugs targeting androgen biosynthesis and the androgen receptor. [miRNA-Seq]

Project description:Inhibition of nucleotide biosynthesis to enhance responses to drugs targeting androgen biosynthesis and the androgen receptor. [miRNA-Seq]

| PRJNA596183 | ENA

Inhibition of nucleotide biosynthesis to enhance responses to drugs targeting androgen biosynthesis and the androgen receptor. [RNA-Seq]

Project description:Inhibition of nucleotide biosynthesis to enhance responses to drugs targeting androgen biosynthesis and the androgen receptor. [RNA-Seq]

| PRJNA596204 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data